Abstract
In the United States (US), there are approximately 10 million office visits annually for vaginal symptoms, of which approximately 20-25% are vulvovaginal candidiasis (VVC). The current approved therapies for treatment of VVC are all azoles which are fungistatic. Here, we introduce oral ibrexafungerp (IBX), a novel triterpenoid antifungal, with fungicidal activity against a broad range of Candida species for treatment of VVC. The purpose of this research is to examine efficacy and safety; and subpopulation outcomes from two phase 3 clinical trials of oral IBX versus Placebo (PLC) in patients with vulvovaginal candidiasis (VVC) in a pooled analysis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
